The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 22, 2021
Filed:
Aug. 18, 2017
National University Corporation Kobe University, Hyogo, JP;
Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, JP;
Osaka Prefectural Hospital Organization, Osaka, JP;
Tatsushi Toda, Hyogo, JP;
Kazuhiro Kobayashi, Hyogo, JP;
Motoi Kanagawa, Hyogo, JP;
Tamao Endo, Tokyo, JP;
Hiroshi Manya, Tokyo, JP;
Yoshinao Wada, Osaka, JP;
Michiko Tajiri, Osaka, JP;
NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, Hyogo, JP;
TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY, Tokyo, JP;
OSAKA PREFECTURAL HOSPITAL ORGANIZATION, Osaka, JP;
Abstract
Provided is a therapeutic agent that effectively acts on a disease associated with abnormal glycosylation of dystroglycan. Also provided is a testing method for diseases associated with abnormal glycosylation of dystroglycan. Specifically, provided is a therapeutic agent for diseases associated with abnormal glycosylation of dystroglycan, containing CDP-ribitol as an active ingredient. Ribitol-phosphate is important in the glycan structure of dystroglycan. In order for ribitol-phosphate to be incorporated into a dystroglycan glycan, a material therefor (sugar donor) is required. In the present invention, it has been found for the first time that CDP-ribitol serves as the sugar donor. It has been confirmed that the glycan of ISPD-deficient cells can be restored by administering CDP-ribitol. Thus, the present invention, which allows CDP-ribitol to be utilized for supplementation therapy, has been completed.